New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
14:41 EDTPACB, ILMN, LMNX, DGX, LH, VCYT, SQNM, QGEN, MYGN, GHDXFDA draft lab tests guidelines not as bad as feared, says Piper Jaffray
After the FDA announced it intends to issue draft guidance on regulations for lab developed tests, Piper Jaffray said the proposed guidelines appear "less onerous" than the firm initially expected. Piper added that the FDA intends to leverage existing studies in lieu of requiring additional studies, which the firm views as positive for companies with well validated offerings such as Genomic Health (GHDX), Myriad Genetics (MYGN), QIAGEN (QGEN), Sequenom (SQNM), and Veracyte (VCYT).
News For GHDX;MYGN;QGEN;SQNM;VCYT;DGX;ILMN;LH;LMNX;PACB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 28, 2015
15:37 EDTQGENNotable companies reporting after market close
Subscribe for More Information
09:22 EDTILMNIllumina price target raised to $230 from $200 at Wedbush
Subscribe for More Information
08:40 EDTILMNIllumina price target raised to $221 from $192 at Janney Capital
Subscribe for More Information
08:27 EDTILMNIllumina price target raised to $234 from $220 at BofA/Merrill
BofA/Merrill raised Buy rated Illumina's price target to $234 citing strong Q4 organic sales momentum.
08:13 EDTQGENQIAGEN management to meet with Evercore ISI
Subscribe for More Information
07:59 EDTILMNIllumina price target raised to $225 from $195 at Leerink
Subscribe for More Information
January 27, 2015
16:09 EDTILMNIllumina sees FY15 non-GAAP EPS $3.12-$3.18, consensus $3.20
For FY15 the Company is projecting approximately 20% revenue growth, assuming current currency exchange rates, and non-GAAP EPS of $3.12-$3.18. These projections assume full year non-GAAP gross margin of approximately 73%, and a pro forma tax rate of approximately 28%.
16:08 EDTILMNIllumina reports Q4 non-GAAP EPS 87c, consensus 78c
Reports Q4 revenue $512M, consensus $507.65M.
16:06 EDTQGENQIAGEN launches monitor to track immune function in organ transplant patients
QIAGEN N.V. announced the commercial launch of QuantiFERON Monitor, a diagnostic for monitoring immune function. QIAGEN is launching QuantiFERON Monitor in Europe as a CE-marked in-vitro diagnostic. Primary applications include monitoring of immune function in solid organ transplant recipients. In North America and other markets, QFM is available for research use as an accurate marker of immune function in studies of immunosuppressive conditions, immune modulating therapies and recovery following transplantation.
15:04 EDTQGENQIAGEN management to meet with Leerink
Meeting to be held in New York on February 3 hosted by Leerink.
January 26, 2015
07:17 EDTMYGNSociety of Thoracic Surgeons to hold annual meeting
51st Annual Meeting of STS is being held in San Diego, California on January 24-28.
January 25, 2015
20:22 EDTLHA small miss for LabCorp could cause a share drop, Barron's says
Subscribe for More Information
January 23, 2015
15:46 EDTMYGN, ILMN, PACB, LMNX, GHDX, SQNMPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
07:32 EDTLHCharles River Labs upgraded to Outperform from Market Perform at William Blair
William Blair upgraded Charles River Labs (CRL) to Outperform citing improving demand for early-stage development services as well as opportunity for share gains due to Covance’s (CVD) pending merger with LabCorp (LH).
January 22, 2015
07:04 EDTSQNMSequenom and Cypher Genomics sign prenatal test development agreement
Subscribe for More Information
January 21, 2015
10:24 EDTILMNIllumina pulls back following State of the Union address
Shares of Illumina (ILMN) rose yesterday after a biotech industry website reported that President Obama might unveil a major new genomics project during his State of the Union address last night. That speculation was backed as a possibility by an analyst at Wells Fargo ahead of last night's address. In the speech, President Obama unveiled what he called his Precision Medicine Initiative, which relies on genomics to "deliver(s) the right treatment at the right time." Obama spent far more time, however, discussing economic growth and foreign relations than healthcare. Illumina shares are down 3% to $190.64 in early trading today.
January 20, 2015
13:45 EDTSQNM, ILMNIllumina rises as genomics project seen being announced in State of the Union
Subscribe for More Information
11:24 EDTILMNIllumina could see headline boost from U.S. genomics project, says Wells Fargo
After biotech industry publication BioCentury said Friday that the president may announce a new genomics project to sequence up to one million human genomes as part of his State of the Union speech tonight, Wells Fargo said that it believes such an announcement could be a headline catalyst for Illumina since it would mean the U.S. needs additional sequencing capacity. However, such a project would be long-term in nature, Wells Fargo cautioned, adding that such a plan would more likely support existing Illumina growth assumptions than push those forecasts up. Shares of Illumina are up 6% to $194.85 in morning trading ahead of tonight's speech by the president.
08:21 EDTLHLabCorp upgraded to Buy from Hold at Evercore ISI
Subscribe for More Information
07:07 EDTMYGNMyriad RBM joins Institut Pasteur in TB collaboration
Myriad RBM, a wholly owned subsidiary of Myriad Genetics, announced that it will assist the Institut Pasteur in a public-private research collaboration to fight the global tuberculosis, or TB, epidemic. This research project is funded by the Bill & Melinda Gates Foundation through a grant to the Institut Pasteur. The proof-of-concept study will evaluate patients with latent and active TB infections who are affiliated with the South African Tuberculosis Vaccine Initiative clinical study sites. The goals of this study are to field-test Myriad RBM's TruCulture system as a point-of-care blood collection and immune response monitoring method and to stratify patients with active and latent tuberculosis.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use